ATLANTA, GA--(Marketwire - Sep 19, 2012) - A class action lawsuit has been filed on behalf of investors who purchased common stock of Vertex Pharmaceuticals Incorporated ("Vertex" or the "Company") (NASDAQ: VRTX) between May 7, 2012 and June 27, 2012. The lawsuit, which was filed in the United States District Court for the District of Massachusetts, alleges Vertex violated the federal securities laws by misrepresenting the results of its Phase 2 study of its experimental drugs VX-909 and Kalydeco in statements made on May 7, 2012 and May 29, 2012. On June 27, 2012 the Company admitted that those prior statements regarding the Phase 2 study were inaccurate and Vertex's stock price declined significantly on the news.

If you purchased Vertex common stock between May 7, 2012 and June 27, 2012, and suffered a net loss on those purchases you have the legal right to petition the Court to be appointed a "lead plaintiff." A lead plaintiff is a representative party that acts on behalf of other class members in directing the litigation. Any such request must satisfy certain criteria and be made no later than November 5, 2012. Any member of the purported class may move the Court to serve as lead plaintiff through counsel of their choice, or may choose to do nothing and remain an absent class member.

Investors who are interested in serving as lead plaintiff or who have questions concerning their legal rights may contact Michael I. Fistel, Jr., Esq. (mfistel@holzerlaw.com) or Marshall P. Dees, Esq. (mdees@holzerlaw.com) by email or via toll-free telephone at (888) 508-6832.

Holzer Holzer & Fistel, LLC dedicates its practice to vigorous representation of shareholders and investors in litigation nationwide, including shareholder class action and derivative litigation. More information about the firm is available through its website, www.holzerlaw.com, and upon request from the firm. Holzer Holzer & Fistel, LLC has paid for the dissemination of this promotional communication, and Michael I. Fistel, Jr. is the attorney responsible for its content.